Back to Search
Start Over
The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19
- Source :
- Antibiotics and Chemotherapy. 66:35-37
- Publication Year :
- 2021
- Publisher :
- Publishing House OKI, 2021.
-
Abstract
- Aim. Evaluation of the efficacy, safety, and tolerability of Riamilovir (trade name «Triazavirin®») in patients with mild COVID-19.Materials and methods. The randomized open-label study included 120 patients with clinical and epidemiological manifestations of coronavirus infection and its laboratory (PCR) confirmation.Results. The efficacy, safety, as well as good tolerability of Riamilovir in the treatment of new coronavirus infection (COVID-19) have been established.Conclusion. The results of the study on the efficacy, safety, and tolerability of Riamilovir allow us to recommend it as a means of etiotropic therapy of the new coronavirus infection (COVID-19).
- Subjects :
- Microbiology (medical)
medicine.medical_specialty
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
business.industry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
General Medicine
030204 cardiovascular system & hematology
medicine.disease_cause
Microbiology
03 medical and health sciences
0302 clinical medicine
Infectious Diseases
Tolerability
Internal medicine
Epidemiology
medicine
030211 gastroenterology & hepatology
In patient
business
Coronavirus
Subjects
Details
- ISSN :
- 02352990
- Volume :
- 66
- Database :
- OpenAIRE
- Journal :
- Antibiotics and Chemotherapy
- Accession number :
- edsair.doi...........de0c0a93fce4e40b0dd5878a043e3cbb